Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy

Abstract

Immunotherapeutic approaches for treating cancer overall have been receiving a considerable amount of interest due to the recent approval of several clinical formulations. Among the different modalities, anticancer vaccination acts by training the body to endogenously generate a response against tumor cells. However, despite the large amount of work that has gone into the development of such vaccines, the near absence of clinically approved formulations highlights the many challenges facing those working in the field. The generation of potent endogenous anticancer responses poses unique challenges due to the similarity between cancer cells and normal, healthy cells. As researchers continue to tackle the limited efficacy of vaccine formulations, fresh and novel approaches are being sought after to address many of the underlying problems. Here the application of nanoparticle technology towards the development of anticancer vaccines is discussed. Specifically, there is a focus on the benefits of using such strategies to manipulate antigen presenting cells (APCs), which are essential to the vaccination process, and how nanoparticle-based platforms can be rationally engineered to elicit appropriate downstream immune responses. Immunotherapeutic approaches to cancer treatment have been gaining significant traction in the clinic. Of the different modalities, the goal of anticancer vaccination is to train the body to detect and eliminate tumors. Here the application of nanoparticle technology towards the development of more effective vaccine formulations that address the limitations of current approaches is discussed.